Gefitinib in non small cell lung cancer.

In addition, exploratory biomarker analyses, including the assessment of EGFR gene copy number by FISH, EGFR and p-AKT protein expression by IHC, EGFR, K-RAS and D-RAF mutational status, showed a trend towards a better survival outcome for gefitinib in patients with high EGFR-gene-copy number (HR 0.61 for high copy number and HR 1.16 for low copy number, P = .045), while patients with EGFR mutations obtained higher RR than wild-type patients (37.5% versus 2.6%) [ 31 ].

also in 28,865 other papers

Differences were not significant for both overall survival (HR 1.24; 95% CI 0.94–1.64; P = .14) and disease-free survival (HR 1.22, 95% CI 0.93–1.61; P = .15), with a negative trend for gefitinib treatment.

also in 2,167 other papers